Cohen & Steers
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Cohen & Steers, Inc. operates as a publicly traded holding company specializing in asset management. Through its various operating units, the firm delivers financial services to institutional investor...
Latest News
3 days ago · prnewswire.com
Cohen & Steers Announces Changes to Realty IndexesNEW YORK, Nov. 13, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Realty Majors Portfolio Index (RMP), Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on November 20, 2026. Cohen & Steers Realty Majors Portfolio Index (RMP) Added component (symbol) Removed component (symbol) American Healthcare REIT, Inc. (AHR.US) VICI Properties, Inc. (VICI.US) Cohen & Steers Global Realty Majors Portfolio Index (GRM) Added component (symbol) Removed component (symbol) American Healthcare REIT, Inc. (AHR.US) VICI Properties, Inc. (VICI.US) Great Portland Estates plc (GPE.LN) Derwent London plc (DLN.LN) Cohen & Steers International Realty Majors Portfolio Index (IRP) Added component (symbol) Removed component (symbol) Great Portland Estates plc (GPE.LN) Derwent London plc (DLN.LN) The GPT Group (GPT.AU) Mapletree Pan Asia Commercial Trust (MPACT.SP) These free-float adjusted, modified market capitalization-weighted total return indexes of selected real estate equity securities are quoted intraday on a real-time basis by the Chicago Mercantile Exchange.
4 days ago · globenewswire.com
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor DayDetailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027
6 days ago · prnewswire.com
Cohen & Steers and DLC Acquire West Street Shopping Center in Keene, New HampshireNEW YORK, Nov. 10, 2026 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that the Cohen & Steers Real Estate Opportunities Fund (REOF) has acquired West Street Shopping Center, a grocery-anchored center in Keene, New Hampshire. The acquisition was made through a joint venture with DLC, a vertically integrated owner and operator of open-air shopping centers.
7 days ago · prnewswire.com
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for October 2026NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $99.6 billion at October 31, 2026, an increase of $3.7 billion from assets under management of $95.9 billion at September 30, 2026. The increase was due to market appreciation of $4.0 billion, partially offset by net outflows of $209 million and distributions of $155 million.
13 days ago · prnewswire.com
Corero Network Security Accelerates International Growth with Strategic Investment in Regional Leadership and PartnershipsNew leadership appointments strengthen EMEA and APAC operations as Corero builds on commercial momentum and industry recognition. LONDON, Nov. 4, 2026 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service ("DDoS") protection specialists and champion of adaptive, real-time service availability, today announced continued investment in its European and international operations, expanding regional leadership, technical expertise, and channel resources to accelerate partner-led growth across Europe, the Middle East, Africa, and Asia-Pacific.
18 days ago · globenewswire.com
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual MeetingPRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 31-November 4 in Washington, D.C. At this year's meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.
18 days ago · prnewswire.com
Cohen & Steers, Inc. Declares Quarterly DividendNEW YORK, Oct. 29, 2026 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the fourth quarter of 2026 in the amount of $0.67 per share of common stock payable on November 19, 2026 to stockholders of record as of the close of business on November 9, 2026. About Cohen & Steers.
20 days ago · businesswire.com
LG CNS and D-Wave Announce Strategic Relationship to Advance Quantum Optimization Adoption in South KoreaSEOUL, South Korea & PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, and LG CNS Co., Ltd. (“LG CNS”), a leading AI transformation company in South Korea, today announced that the companies have signed a non-binding memorandum of understanding (“MOU”) to advance the adoption of quantum computing for enterprise optimization in.
29 days ago · fool.com
Cohen & Steers: 3 Key Takeaways for Long-Term InvestorsCohen & Steers generated $1.6 billion in third-quarter net inflows. The institutional pipeline reached $1.9 billion.
29 days ago · businesswire.com
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesPRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CNS